Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

1.57
+0.06104.04%
Volume:674.97K
Turnover:1.05M
Market Cap:181.22M
PE:-1.19
High:1.59
Open:1.51
Low:1.49
Close:1.51
52wk High:1.94
52wk Low:0.6611
Shares:115.35M
Float Shares:100.80M
Volume Ratio:2.29
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3180
EPS(LYR):-1.6384
ROE:-52.35%
ROA:-23.85%
PB:0.77
PE(LYR):-0.96

Loading ...

Fate Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 05, 2025

Fate Therapeutics Shares Rise After HC Wainwright Upgrade

MT Newswires Live
·
Nov 01, 2025

HC Wainwright Upgrades Fate Therapeutics to Buy From Neutral, $5 Price Target

MT Newswires Live
·
Oct 31, 2025

Fate Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
Oct 31, 2025

Fate Therapeutics Inc : H.c. Wainwright Raises to Buy From Neutral

THOMSON REUTERS
·
Oct 31, 2025

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

TIPRANKS
·
Oct 27, 2025

Fate Therapeutics Raised to Outperform From Neutral by Wedbush

Dow Jones
·
Oct 27, 2025

Fate Therapeutics Inc : Wedbush Raises to Outperform From Neutral Rating; Raises Target Price to $7 From $5

THOMSON REUTERS
·
Oct 27, 2025

Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns

TIPRANKS
·
Oct 27, 2025

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

GlobeNewswire
·
Oct 26, 2025

Fate Therapeutics Inc. Files Initial Beneficial Ownership Statement for CFO Kamal Adawi

Reuters
·
Oct 22, 2025

Fate Therapeutics Appoints New CFO Kamal Adawi

TIPRANKS
·
Oct 15, 2025

Fate Therapeutics Names Kamal Adawi Chief Financial Officer

Dow Jones
·
Oct 14, 2025

Fate Therapeutics appoints Adawi as CFO

TIPRANKS
·
Oct 14, 2025

Press Release: Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

Dow Jones
·
Oct 14, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Oct 03, 2025

Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 62% over the previous year

Simply Wall St.
·
Oct 01, 2025

Fate Therapeutics Announces New Employee Inducement Awards Under Nasdaq Rule 5635(c)(4)

Reuters
·
Sep 04, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Sep 04, 2025